Citius Moves Forward with Mino-Lok™ Phase 3 Trial

Manufacturing Finalized and Site Recruitment Initiated PR Newswire, CTXR CRANFORD, N.J., Dec. 8, 2016 CRANFORD, N.J., Dec. 8, 2016 /PRNewswire/  Citius Pharmaceuticals, Inc. ( Citius ) (OTC BB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, provided details of its phase 3 trial for Mino-Lok™, an antibiotic lock solution used to salvage infected central venous catheters (CVCs) and to treat catheter related bloodstream infections (CRBSIs).  Mino-Lok is being developed as an adjunctive therapy for the treatment of
http://bit.ly/2geLm40